Novartis AG ADR (NVS)vsTwist Bioscience Corp (TWST)
NVS
Novartis AG ADR
$140.98
+0.21%
HEALTHCARE · Cap: $260.70B
TWST
Twist Bioscience Corp
$164.60
-0.74%
HEALTHCARE · Cap: $11.07B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 13030% more annual revenue ($56.69B vs $431.80M). NVS leads profitability with a 22.5% profit margin vs -31.7%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
TWST
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-50.3%
Fair Value
$93.40
Current Price
$140.98
$47.58 premium
Margin of Safety
+57.1%
Fair Value
$115.60
Current Price
$164.60
$49.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Conservative balance sheet, low leverage
Revenue surging 23.2% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Trading at 23.2x book value
ROE of -17.9% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : TWST
The strongest argument for TWST centers on Debt/Equity, Revenue Growth. Revenue growth of 23.2% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : TWST
The primary concerns for TWST are EPS Growth, Price/Book, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while TWST is a growth play — different risk/reward profiles.
TWST carries more volatility with a beta of 2.22 — expect wider price swings.
TWST is growing revenue faster at 23.2% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 29/100), backed by strong 22.5% margins. TWST offers better value entry with a 57.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Twist Bioscience Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?